2015-06-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/683362摘要：心血管疾病在現今全球國際社會中，已成為快速成長的重要文明病，而預後照護的支出更是沉重而長期的負擔。有鑑於此，我們預定新創的公司是以台灣大學研發團隊於生醫電子晶片技術之經驗為基礎，結合電子與醫療照護兩大台灣產業技術主軸，發展快速低成本心血管疾病生物標誌分子分析技術，開發高準確度快速篩檢的point-of-care(POC)平台。團隊的主要核心競爭力是建立在應用半導體奈微米製程技術與先進的生物分子分析技術，以發展下一代多分子指標及高準確度快速體外診斷醫療器材(In Vitro Diagnostic Devices，IVD)，並具有通訊功能，可把資訊即時送出給醫療照護人員，以利後續必要的快速治療流程。我們首推的產品，可在心血管疾病中針對急性心肌梗塞診斷及預後照護，最主要的生物指標(Biomarkers) Troponin I進行快速檢測，提供使用者快速及方便地監測重要的生物指標(biomarkers)。此產品不但可應用在心血管疾病，針對不同的生物指標分子也可以進行檢測，進一步拓展成為其他疾病診斷之應用。<br> Abstract: Cardiac diseases have become a major disease in world wide. In addition, the cost of cardiac diseases diagnosis and prognosis increases with the development of modern societies. To overcome this challenge and offer well-being technology for human, a low-cost and high-sensitive biomolecular diagnosis platform will be developed by harnessing davantages of electronics and healthcare. Based on preivous development of bioelecotronic chip, a point-of-care (POC) biomolecular diagnosis chip can be implemented. The major competence of thistechnology is the semiconductor fabricated chip for In-Vitro Diagnosis (IVD) in biomolecular analysis technology. This integration not only promotes a low-cost manufacturing technology but also offers a high-accurate analysis technique for IVD applications. To demostrate this advantage, a biomarker, Troponin I, for acute myocardial infarction (AMI) diagnosis is proposed to be implemented by the developed technology. The developed product can be a fast method to monitor and analyze this important biomarker. Moreover, similar products can also be applied for other disease diagnosis in the future.心血管疾病快速體外診斷醫療器材定點照護Cardiac diseasesIn Vitro Diagnostic DevicesPoint of care